

## Magle Chemoswed Q3 - Record high sales bolstered by merger

Redeye provides a research update following the Q3 report recently published by Magle. Following the merger and acquisitions of pK Chemicals and Amniotics, we believe that Magle is poised to generate long-term shareholder value. Furthermore, the company reported record high sales figures at SEK64.6, a 78% y/y growth, with an impressive 32% EBITDA margin. We reiterate our fair value range (SEK30 – SEK70) with a base case valuation of SEK50.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

[Magle Chemoswed Q3 - Record high sales bolstered by merger](#)